Objectives: The purpose of this study was to characterize health status outcomes after
transcatheter aortic valve replacement (TAVR) with a self-expanding bioprosthesis among …

Abstract Objectives: The UK Transcatheter Aortic Valve Implantation Registry reported 30-
day and 1-year mortality rates of 7.1% and 21.4%, respectively, for patients who underwent …

Objectives: This study sought to evaluate clinical outcomes and transcatheter heart valve
hemodynamics at 1 year after transcatheter aortic valve replacement (TAVR) in low-risk …

Background: A series of models have been developed to identify patients at high risk for
poor outcomes after transcatheter aortic valve replacement (TAVR) to help guide treatment …

Abstract Background: The CoreValve US Pivotal High Risk Trial was the first randomized
trial to show superior 1-year mortality of transcatheter aortic valve replacement (TAVR) …

Objective Transcatheter aortic valve implantation (TAVI) has emerged as an alternative
treatment to aortic valve replacement (AVR) for selected patients with severe aortic stenosis …

Background—The proven efficacy of transcatheter aortic valve implantation (TAVI) in high-
risk patients is leading to the expansion of its indications toward lower-risk patients …

Transcatheter aortic valve replacement (TAVR) has been recognized as a well-established
alternative to surgical aortic valve replacement (SAVR) for symptomatic aortic stenosis with …

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of severe
aortic stenosis (AS) over the last decade. The results of the Placement of Aortic …

Background: In patients with severe aortic stenosis, treatment with transcatheter aortic valve
replacement (TAVR) has been shown to be cost-effective in the high-risk surgical population …